Clinical response | Serum trough infliximab levels at 14 weeks | |||
---|---|---|---|---|
Low (0–1.2 mg/l) | Intermediate (1.3–4.7 mg/l) | High (5.0–25.8 mg/l) | Significance | |
*Indicates statistical significance, NS indicates no statistical significance. | ||||
Mean DAS28, t = 0 | 6.4 | 6.1 | 5.8 | NS |
Mean CRP, t = 0 | 49 | 29 | 17 | * |
EULAR responders (%) | 50 | 90 | 88 | * |
Mean change in DAS28 between | ||||
0–2 Weeks | −1.3 | −1.2 | −1.1 | NS |
2–6 Weeks | −0.4 | −0.7 | −1.0 | NS |
6–14 Weeks | 0.9 | −0.1 | −0.2 | * |
0–14 Weeks | −0.9 (−1.4) | −2.0 (−1.3) | −2.4 (−1.4) | * |